ATE512661T1 - Verwendung eines betablockers zur herstellung eines arzneimittels zur behandlung von hämangiomen - Google Patents

Verwendung eines betablockers zur herstellung eines arzneimittels zur behandlung von hämangiomen

Info

Publication number
ATE512661T1
ATE512661T1 AT08838691T AT08838691T ATE512661T1 AT E512661 T1 ATE512661 T1 AT E512661T1 AT 08838691 T AT08838691 T AT 08838691T AT 08838691 T AT08838691 T AT 08838691T AT E512661 T1 ATE512661 T1 AT E512661T1
Authority
AT
Austria
Prior art keywords
hemangiomas
treatment
production
medicinal product
beta blocker
Prior art date
Application number
AT08838691T
Other languages
English (en)
Inventor
Christine Leaute-Labroze
De La Roque Eric Dumas
Alain Taieb
Jean-Benoit Thambo
Original Assignee
Univ Victor Segalen Bordeaux 2
Ct Hospitalier Universitaire De Bordeaux
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39156667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE512661(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Victor Segalen Bordeaux 2, Ct Hospitalier Universitaire De Bordeaux filed Critical Univ Victor Segalen Bordeaux 2
Application granted granted Critical
Publication of ATE512661T1 publication Critical patent/ATE512661T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT08838691T 2007-10-19 2008-10-16 Verwendung eines betablockers zur herstellung eines arzneimittels zur behandlung von hämangiomen ATE512661T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07291273A EP2050441A1 (de) 2007-10-19 2007-10-19 Verwendung von Beta-Blockern für die Herstellung eines Medikaments zur Behandlung von Hämangiomen
US98950707P 2007-11-21 2007-11-21
PCT/IB2008/002746 WO2009050567A2 (en) 2007-10-19 2008-10-16 Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas

Publications (1)

Publication Number Publication Date
ATE512661T1 true ATE512661T1 (de) 2011-07-15

Family

ID=39156667

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08838691T ATE512661T1 (de) 2007-10-19 2008-10-16 Verwendung eines betablockers zur herstellung eines arzneimittels zur behandlung von hämangiomen

Country Status (31)

Country Link
US (2) US8338489B2 (de)
EP (3) EP2050441A1 (de)
JP (1) JP5552700B2 (de)
KR (2) KR20150110827A (de)
CN (2) CN102006864B (de)
AR (1) AR068927A1 (de)
AT (1) ATE512661T1 (de)
AU (1) AU2008313405B2 (de)
BR (1) BRPI0816536A2 (de)
CA (1) CA2701953C (de)
CL (1) CL2008003083A1 (de)
CO (1) CO6270209A2 (de)
CY (1) CY1112604T1 (de)
DE (1) DE08838691T1 (de)
DK (2) DK2187878T3 (de)
ES (2) ES2368299T3 (de)
HK (1) HK1148940A1 (de)
HR (2) HRP20110659T1 (de)
IL (1) IL205129A (de)
MA (1) MA31843B1 (de)
MX (1) MX2010004295A (de)
MY (1) MY156750A (de)
NZ (1) NZ584307A (de)
PA (1) PA8799401A1 (de)
PL (2) PL2187878T3 (de)
PT (2) PT2187878E (de)
RU (1) RU2471500C2 (de)
SI (2) SI2233135T1 (de)
TN (1) TN2010000170A1 (de)
TW (1) TWI531365B (de)
WO (1) WO2009050567A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8987262B2 (en) 2007-10-19 2015-03-24 Universite de Bordeaux Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
EP2050441A1 (de) 2007-10-19 2009-04-22 Université Victor Segalen Bordeaux 2 Verwendung von Beta-Blockern für die Herstellung eines Medikaments zur Behandlung von Hämangiomen
US8633181B2 (en) 2009-04-09 2014-01-21 Rutgers, The State University Of New Jersey Treatment of cutaneous hemangioma
EP2246044A1 (de) 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Kinderärztliche Lösungen für Betablocker
WO2012125413A2 (en) * 2011-03-12 2012-09-20 Vicus Therapeutics, Llc Compositions for ameliorating systemic inflammation and methods for making and using them
CN102579412A (zh) * 2012-02-16 2012-07-18 山东省立医院 一种治疗婴幼儿血管瘤的外用药物及其制备方法
CN103536607A (zh) * 2012-07-10 2014-01-29 邵金辉 土霉素，普罗帕酮和安乃近的抗肿瘤作用
CN103054793B (zh) * 2013-01-05 2015-01-21 广州军区广州总医院 一种用于治疗婴幼儿血管瘤的盐酸普萘洛尔乳膏及其制备方法
WO2014150899A1 (en) * 2013-03-15 2014-09-25 Chapin Matthew J Topical ophthalmic formulations for treating migraine
CN104274390B (zh) * 2014-09-04 2017-06-13 郑家伟 一种噻吗洛尔长效透皮制剂及其在血管瘤中的应用
RU2584082C1 (ru) * 2015-01-21 2016-05-20 Ильдар Наилевич Нурмеев Способ лечения гемангиом
CN105434337B (zh) * 2015-04-03 2019-08-16 武汉科福新药有限责任公司 盐酸普萘洛尔亚微乳凝胶及其制备方法和用途
CN105106105A (zh) * 2015-08-14 2015-12-02 天津市聚星康华医药科技有限公司 噻吗洛尔外用制剂治疗婴幼儿血管瘤的应用及其制备方法
US20170360829A1 (en) * 2016-01-27 2017-12-21 Gillies Mcindoe Research Institute Treatment of vascular anomalies
RU2617516C1 (ru) * 2016-03-24 2017-04-25 Государственное бюджетное учреждение здравоохранения города Москвы Научно-исследовательский институт неотложной детской хирургии и травматологии Департамента здравоохранения города Москвы Способ лечения младенческих гемангиом
CN106474061B (zh) * 2016-12-08 2019-01-22 黑龙江童医生儿童生物制药有限公司 一种盐酸普萘洛尔口服乳剂及其制备方法
CN108261411B (zh) * 2016-12-30 2021-04-30 武汉科福新药有限责任公司 用于婴幼儿血管瘤治疗的口腔膜剂及其制备方法
US11730707B2 (en) 2017-08-07 2023-08-22 Alianza Española De Familias De Von Hippel-Lindau-Vhl Compounds for treating von Hippel-Lindau disease
CN108299279B (zh) * 2018-02-09 2021-03-23 北京梅尔森医药技术开发有限公司 取代芳基胺醇化合物及其制备方法和用途
CN110314154A (zh) * 2018-03-28 2019-10-11 武汉恒信源药业有限公司 左旋普萘洛尔在制备治疗血管病变药物中的应用
US20210346319A1 (en) * 2018-10-04 2021-11-11 Emory University Pharmaceutical Compositions of R-(+)-Propranolol in Enantiomeric Excess and Therapeutic Uses Related Thereto
RU2701213C1 (ru) * 2018-12-27 2019-09-25 Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Способ лечения инфантильных гемангиом
US11154518B2 (en) * 2018-12-28 2021-10-26 Chang Gung Memorial Hospital, Linkou Methods and apparatus for treating a wound
WO2020242962A1 (en) * 2019-05-24 2020-12-03 Pediatric Derm Developement Llc Treatment of infantile hemangioma
CN111773226A (zh) * 2019-06-26 2020-10-16 首都医科大学附属北京儿童医院 噻吗洛尔或其盐在制备预防和/或治疗丛状血管瘤的药物中的用途
MX2022009258A (es) * 2020-01-29 2022-11-09 Massey Ventures Ltd Metodos y composiciones para el tratamiento del hemangioma.
TWI813331B (zh) * 2020-07-10 2023-08-21 長庚醫療財團法人林口長庚紀念醫院 β-1腎上腺素受體拮抗劑用於製備減少表皮生長因子受體抑制劑誘導的上皮細胞損傷以及抑制癌細胞的組合物之用途
CN116472036A (zh) 2020-09-30 2023-07-21 日产化学株式会社 包含水溶性β阻断剂及卵磷脂的复合体
CN113274348A (zh) * 2021-06-11 2021-08-20 四川大学华西医院 用于治疗婴幼儿血管瘤的阿替洛尔凝胶、制备方法及应用
PL244294B1 (pl) * 2022-09-20 2024-01-03 Univ Medyczny W Lodzi Kompozycja farmaceutyczna do stosowania miejscowego oraz jej zastosowanie w leczeniu naczyniaków krwionośnych u dzieci

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL301580A (de) 1962-12-11
US3466325A (en) 1965-04-30 1969-09-09 Haessle Ab 1-(ortho-alkenyl phenoxy) - 2-hydroxy-3-isopropylaminopropanes and the salts thereof
US3657237A (en) 1968-05-22 1972-04-18 Frosst & Co Charles E Process for making 1 2 5-thiadiazoles in the sinister configuration
GB1253709A (en) 1968-05-22 1971-11-17 Frosst & Co Charles E Thiadiazole derivatives
US3655663A (en) 1969-04-21 1972-04-11 Burton K Wasson 4-(3-secondary amino-2-hydroxy-proxy) 1 2 5-thiadiazoles
SE354851B (de) 1970-02-18 1973-03-26 Haessle Ab
AT334385B (de) 1973-12-20 1976-01-10 Chemie Linz Ag Verfahren zur herstellung von neuen phenoxypropylaminderivaten und deren salzen
FR2330383A1 (fr) 1975-11-06 1977-06-03 Synthelabo Nouveaux ethers de phenols substitues, leurs sels, leur preparation et les medicaments qui les renferment
US5116867A (en) * 1989-06-30 1992-05-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services D-propranolol as a selective adenosine antagonist
US5182102A (en) * 1991-07-12 1993-01-26 Alcon Laboratories, Inc. Anti-glaucoma compositions
DE69434048T2 (de) * 1993-07-19 2005-10-06 Angiotech Pharmaceuticals, Inc., Vancouver Anti-angiogene Mittel und Verfahren zu deren Verwendung
US6232299B1 (en) * 1996-05-01 2001-05-15 Eli Lilly And Company Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
CZ350098A3 (cs) * 1996-05-01 1999-11-17 Eli Lilly And Company Způsob léčení neoplasie
GB9616672D0 (en) * 1996-08-08 1996-09-25 Scherer Ltd R P Pharmaceutical compositions
JP2004528378A (ja) 2001-05-08 2004-09-16 シエーリング アクチエンゲゼルシャフト Ｎ−オキシドアントラニルアミド誘導体と医薬製剤としての利用
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
WO2006015830A1 (en) * 2004-08-09 2006-02-16 Universite Catholique De Louvain Use of agonists and antagonists of beta-adrenoceptors for treating arterial diseases
TW200716141A (en) * 2005-05-05 2007-05-01 Combinatorx Inc Compositions and methods for treatment for neoplasms
EP2050441A1 (de) 2007-10-19 2009-04-22 Université Victor Segalen Bordeaux 2 Verwendung von Beta-Blockern für die Herstellung eines Medikaments zur Behandlung von Hämangiomen
US8987262B2 (en) 2007-10-19 2015-03-24 Universite de Bordeaux Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas

Also Published As

Publication number Publication date
RU2010112816A (ru) 2011-11-27
BRPI0816536A2 (pt) 2017-06-06
EP2233135B8 (de) 2013-07-10
CN103169971A (zh) 2013-06-26
CN102006864A (zh) 2011-04-06
WO2009050567A3 (en) 2009-06-18
PL2233135T3 (pl) 2012-11-30
PA8799401A1 (es) 2009-05-15
HK1148940A1 (en) 2011-09-23
SI2233135T1 (sl) 2012-10-30
JP5552700B2 (ja) 2014-07-16
AR068927A1 (es) 2009-12-16
EP2233135A1 (de) 2010-09-29
ES2390534T3 (es) 2012-11-13
EP2233135B1 (de) 2012-06-27
JP2011500661A (ja) 2011-01-06
EP2187878A2 (de) 2010-05-26
CY1112604T1 (el) 2016-02-10
TW200932207A (en) 2009-08-01
HRP20120765T1 (hr) 2012-10-31
CO6270209A2 (es) 2011-04-20
ES2368299T3 (es) 2011-11-16
US20130072551A1 (en) 2013-03-21
RU2471500C2 (ru) 2013-01-10
MY156750A (en) 2016-03-31
SI2187878T1 (sl) 2011-10-28
US8338489B2 (en) 2012-12-25
PL2187878T3 (pl) 2012-01-31
CL2008003083A1 (es) 2009-03-06
US9173858B2 (en) 2015-11-03
MX2010004295A (es) 2010-08-02
IL205129A0 (en) 2010-11-30
AU2008313405B2 (en) 2013-12-19
WO2009050567A2 (en) 2009-04-23
PT2187878E (pt) 2011-09-07
TN2010000170A1 (en) 2011-11-11
MA31843B1 (fr) 2010-11-01
PT2233135E (pt) 2012-09-06
CA2701953C (en) 2015-05-19
KR20150110827A (ko) 2015-10-02
EP2050441A1 (de) 2009-04-22
NZ584307A (en) 2012-03-30
DK2187878T3 (da) 2011-09-19
IL205129A (en) 2015-05-31
HRP20110659T1 (hr) 2011-10-31
AU2008313405A1 (en) 2009-04-23
KR20100087012A (ko) 2010-08-02
TWI531365B (zh) 2016-05-01
US20100273889A1 (en) 2010-10-28
CN102006864B (zh) 2013-01-16
KR101562627B1 (ko) 2015-10-22
DK2233135T3 (da) 2012-10-01
CA2701953A1 (en) 2009-04-23
DE08838691T1 (de) 2010-08-26
EP2187878B1 (de) 2011-06-15

Similar Documents

Publication Publication Date Title
ATE512661T1 (de) Verwendung eines betablockers zur herstellung eines arzneimittels zur behandlung von hämangiomen
GB2453188B (en) Use of compounds in the manufacture of medicaments for treatment of regional fat deposits
IL205671A0 (en) Novel cyclic hydrocarbon compounds for the treatment of diseases
IL216967A0 (en) 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives, method of production thereof and use thereof for the treatment of diseases
IL204556A0 (en) (cyclopropyl-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
ATE477798T1 (de) Verwendung von agomelatin zur herstellung von medikamenten zur behandlung der generalisierten angststörung
DE502008000313D1 (de) Verfahren zur kontinuierlichen Herstellung von Aminoalkylgruppen aufweisenden Organopolysiloxanen
DE602007012189D1 (de) Maschine zur Herstellung von Filtern für Tabakprodukte
IL188541A0 (en) Process for the treatment of organic waste and product obtained thereof
ATE520393T1 (de) Verwendung von cb1-rezeptor-antagonisten zur herstellung eines arzneimittels zur behandlung von lebererkrankungen
DE502008000497D1 (de) Verfahren zur Herstellung eines Tuftprodukts, Tuftprodukt und dessen Verwendung
ATE381929T1 (de) Verwendung von resveratrol zur herstellung eines arzneimittels zur behandlung von grippe
DE112008003087A5 (de) Verfahren zur Verbesserung der hydrophilen Eigenschaften von Produkten, ein Zement und ein Celluloseether mit vorteilhaften hydrophilen Eigenschaften sowie die Verwendung von Plasma zur Behandlung von Produkten
GB0724226D0 (en) Composition for the treatment of a detached retina and method of production thereof
ATE491443T1 (de) Verwendung des agomelatins zur herstellung eines medikamentes zur behandlung der bipolaren erkrankungen
DE602005000442D1 (de) Verwendung von alpha-1-Antitrypsin zur Herstellung eines Medikaments zur Behandlung von Fibromyalgie
ATE481393T1 (de) Neue cycloalkyl-benzothiadiazin-derivate, ihr herstellungsverfahren und die pharmazeutischen zusammensetzungen, die sie enthalten
ATE501717T1 (de) Einsatz von agomelatin zur herstellung von medikamenten zur behandlung des smith-magenis- syndroms (sms)
DE602008001384D1 (de) Maschine zur Herstellung und/oder Verpackung von Tabakerzeugnissen
PL2307380T3 (pl) Pochodne N’-nitroksyalkilonikotynamidu do leczenia chorób układu sercowo-naczyniowego
ATE527997T1 (de) Verwendung von aminapthon zur herstellung eines medikaments zur behandlung von arteriopathien
DE112009003270A5 (de) Filtereinsatz und verfahren zur herstellung des filtereinsatzes
ATE483458T1 (de) Einsatz von agomelatin zur herstellung von medikamenten zur behandlung von periventrikulärer leukomalazie
ATE498391T1 (de) Flüssige zusammensetzung für die behandlung und/oder verhinderung von verschiedenen metabolischen knochenkrankheiten, verwendung davon und vorbereitungsprozess.
ATE452633T1 (de) VERWENDUNG EINER ANTI-ATHEROTHROMBOTISCHEN SUBSTANZ ZUR HERSTELLUNG VON ARZNEIMITTELN ZUR BEHANDLUNG VON ZEREBRALEN GEFÄßSTÖRUNGEN

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2187878

Country of ref document: EP